Covidien jettisons specialty chemicals unit
May 26, 2010 by MassDevice staff
Covidien plc sells its specialty chemicals business to New Mountain Capital L.L.C. for $280 million in cash.
Covidien plc (NYSE:COV) sold its specialty chemical unit to New York-based private equity firm New Mountain Capital LLC for $280 million in cash.
The sale involves the J.T. Baker and Mallinckrodt Laboratory Chemicals brands, which are based in Phillipsburg, N.J. Covidien said it expects the deal to close by the end of fiscal 2010.
- Login to post comments
-
Permalink
RECENT BLOG POSTS
- Patient and family engagement in ICUs
- A day in the life: A pediatric neurosurgeon's vision
- Medical Device Tax: Are Conservatives' goals hampering repeal efforts?
- Personal health record use by adolescents
- Can Johnson & Johnson fire on all cylinders again?
- U.S. FDA to require proof of IEC 60601-1 3rd Edition in summer 2013
- A cure for coffee breath?
- A Goldilocks approach to leaky blood vessels: Not too stiff, but not too loose
- Optimizing electronic medication administration records
- A bold new vision for Meditech
Navigation
NEWS
Symbios recalls GoPump and GOBlock kits following patient complaints
Symbios Medical Products recalls 2 years' worth of its GoPump systems and GOBlock kits after...
Covidien launches its new respiratory monitoring device
Covidien's MicroStream MicroPod respiratory monitoring module hits the shelves
New Xbox One Kinect game system can measure heartbeat visually | MassDevice.com On Call
The newly unveiled iteration of the Microsoft Xbox One's Kinect camera demonstrates the ability to...
MassDevice.com +3 | The top 3 med-tech stories for May 22, 2013
If you read nothing else today, make sure you're still in the know with MassDevice +3.
FDA's Ortho Panel supports down-classification of pedicle screw spinal systems
The FDA's Orthopedic & Rehabilitations Devices Panel agrees with the FDA's recommendations that...
